AbbVie has reported net revenues of nearly $56.2bn for the full year 2021 on a GAAP Basis, representing a rise of 22.7% compared to $45.8bn for the full year 2020.
For the 12 months ending on 31 December 2021, the GAAP diluted earnings per share (EPS) surged by 137.1% to $6.45 from $2.72 for the full year 2020.
Global net revenues from the immunology portfolio for the full year totalled $25.28bn, reflecting a 14.1% growth on a reported basis or 13.5% on an operational basis.
Humira generated net revenues of $17.33bn in the US during this period, a 7.6% rise, while globally the figures stood at $3.36bn, a decline of 9.6%.
AbbVie attributed the drop in the international net revenue of Humira to biosimilar competition.
Internationally, Skyrizi and Rinvoq generated net revenues of $2.94bn and $1.65bn, respectively.
During the 12 months, the hematologic oncology and neuroscience portfolios generated nearly $7.23bn and $5.93bn in global net revenues, respectively, up 8.7% and 69.5%, on a reported basis.
AbbVie chairman and CEO Richard Gonzalez said: “We delivered another year of outstanding performance in 2021 with double-digit revenue and EPS growth that were well above our initial expectations.
“We are entering 2022 with significant momentum and expect our diverse set of growth assets, robust pipeline and excellent execution to deliver continued strong performance this year and over the long term.”
Furthermore, the company’s global net revenues during the fourth quarter (Q4) of 2021 increased by 7.4% on a reported basis to $14.88bn.
For the quarter, global net revenues from the immunology, hematologic oncology and neuroscience portfolio were $6.75bn, $1.87bn and $1.65bn, respectively.
In the second quarter (Q2) of 2021, AbbVie reported global net revenues of nearly $14bn indicating a surge of 33.9% on a reported basis.